← Back to Search

Nonsteroidal Anti-inflammatory Drug

Nurtec (Rimegepant) Group for Pain

Phase 4
Waitlist Available
Led By Sergey Motov, MD
Research Sponsored by Antonios Likourezos
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 60 minutes
Awards & highlights

Study Summary

This trial is studying whether using a standardized medication protocol for treating people with migraines in the emergency room results in better patient outcomes than the current standard of care, which can vary depending on the physician, institution, and patient preferences.

Eligible Conditions
  • Pain

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~60 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Pain Score at 60 Minutes

Trial Design

2Treatment groups
Active Control
Group I: Nurtec (Rimegepant) GroupActive Control1 Intervention
Drug: 75 mg of ODT
Group II: AOK GroupActive Control1 Intervention
Drug: Proprietary oral formulation of 0.85mg/kg of ketamine + 324mg of aspirin

Find a Location

Who is running the clinical trial?

Antonios LikourezosLead Sponsor
38 Previous Clinical Trials
8,573 Total Patients Enrolled
17 Trials studying Pain
1,420 Patients Enrolled for Pain
Sergey Motov, MDPrincipal InvestigatorMaimonides Medical Center
16 Previous Clinical Trials
1,510 Total Patients Enrolled
10 Trials studying Pain
940 Patients Enrolled for Pain
Leily Naraghi, MDPrincipal InvestigatorMaimonides Medical Center
1 Previous Clinical Trials
1 Trials studying Pain

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache
Antonios Likourezos 2021. "An Efficacy and Safety of Proprietary Formulations of Oral Ketamine + Aspirin in Treatment of Acute Headache". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04860713.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top